HCPLive

JUNE 23, 2024

In the special on-site ADA 2024 episode, hosts are joined by the ADA's Chief Scientific and Medical Officer Robert Gabbay, MD, PhD, to discuss the newly formed Obesity Association.

Obesity 83

Obesity Diabetes 83

American College of Cardiology

JULY 16, 2024

For patients with obesity-related heart failure with preserved ejection fraction (HFpEF), what is the effect of semaglutide on change in New York Heart Association (NYHA) functional class over time?

Preserved Ejection Fraction 58

Preserved Ejection Fraction Obesity Heart Failure Article 58

HCPLive

JUNE 21, 2024

In retrospective, observational research at ADA 2024, real-world weight loss was linked to a reduction in the risk of obesity-related cancers.

Obesity 80

Obesity Cancer Research 80

American College of Cardiology

JULY 24, 2024

The following are key points to remember from a review of medications used to treat obesity.

Obesity 49

Obesity Article 49

Cardiometabolic Health Congress

JANUARY 3, 2024

In today’s society, the prevalence of obesity has become a significant concern. have obesity, and this rate has increased by more than 10 percentage points in the past two decades. Understanding the prevalence of obesity is crucial in comprehending why events like Healthy Weight Week are essential. of adults in the U.S.

Obesity 97

Obesity Diabetes Blood Pressure BMI 97

Med Page Today

APRIL 18, 2024

(MedPage Today) -- Tirzepatide (Zepbound) injections reduced sleep apnea severity among patients with obesity, regardless of positive airway pressure (PAP) use, according to topline data from two phase III trials. In the SURMOUNT-OSA 1 study.

Obesity 96

Obesity 96

Med Page Today

JUNE 24, 2024

(MedPage Today) -- Metabolic surgery became the first therapy associated with a reduction in incident cardiovascular disease and death among patients with obesity and obstructive sleep apnea (OSA), based on a retrospective cohort study. Such patients.

Obesity 79

Obesity Cardiovascular Disease 79

HCPLive

FEBRUARY 2, 2024

Obesity was linked to an increased risk of focal segmental glomerulosclerosis and hypertensive nephropathy, with further analysis revealing its impact on the risk of developing end-stage kidney disease.

Kidney Disease 105

Kidney Disease Obesity Hypertension 105

HCPLive

JUNE 21, 2024

Atul Malhotra, MD, discusses the results of the SURMOUNT-OSA trial and how they inform clinicians on the role of tirzepatide in OSA and obesity.

Obesity 75

Obesity 75

HCPLive

FEBRUARY 5, 2024

Tirzepatide, a dual GLP-1/GIP agonist approved for diabetes and obesity, was associated with significant blood pressure reductions in an analysis of the SURMOUNT-1 trial.

Blood Pressure 116

Blood Pressure Obesity Diabetes 116

Circulation

MAY 20, 2024

Obesity is a recognized public health epidemic with a prevalence that continues to increase dramatically in nearly all populations, impeding progress in reducing incidence rates of cardiovascular disease. Circulation, Ahead of Print.

Obesity 78

Obesity Public Health Research Cardiovascular Disease 78

HCPLive

FEBRUARY 14, 2024

Patients with ACPA-positive RA and obesity had greater DAS44 scores compared to normal-weight patients, although this difference was not present in ACPA-negative RA.

Obesity 105

Obesity 105

Journal of Clinical Investigation - Cardiology

FEBRUARY 1, 2024

Nonalcoholic fatty liver disease (NAFLD) is prevalent in the majority of individuals with obesity, but in a subset of these individuals, it progresses to nonalcoholic steatohepatitis (0NASH) and fibrosis. The mechanisms that prevent NASH and fibrosis in the majority of patients with NAFLD remain unclear.

Obesity 109

Obesity Diet 109

American Heart News - Heart News

FEBRUARY 5, 2024

Research Highlights: The weight loss medication tirzepatide significantly lowered the systolic blood pressure of nearly 500 adults who had obesity and took the medication for 36 weeks, or about eight months, in a subset of an international clinical.

Blood Pressure 115

Blood Pressure Obesity Research 115

American Heart News - Heart News

JANUARY 17, 2024

Research Highlights: Consistently high scores of perceived stress during adolescence through adulthood may contribute to worse cardiometabolic health including obesity in young adults. Researchers suggest the adoption of healthy coping strategies.

Obesity 119

Obesity Blood Pressure Diabetes Research 119

Science Daily - Heart Disease

JANUARY 17, 2024

Young adults who reported higher stress as adolescents were more likely to have high blood pressure, obesity and other cardiometabolic risk factors as adults, finds new study.

Blood Pressure 100

Blood Pressure Obesity Risk Factors Diabetes 100

Medical Xpress - Cardiology

JANUARY 16, 2024

Obesity-induced heart disease, which affects up to 10% of the population in certain age ranges, is considered an untreatable condition and 75% of people don't survive more than five years beyond diagnosis.

Obesity 91

Obesity Heart Disease Research 91

Medical Xpress - Cardiology

JULY 9, 2024

Semaglutide reduces cardiovascular events, regardless of baseline glycated hemoglobin (HbA1c), among people with overweight or obesity and established atherosclerotic cardiovascular disease, according to a study published online June 22 in Diabetes Care.

Obesity 52

Obesity Cardiovascular Disease Diabetes 52

Cardiovascular Diabetology

APRIL 1, 2024

Obesity is often associated with multiple comorbidities. However, whether obese subjects with hyperlipidemia in the absence of other complications have worse cardiac indices than metabolically healthy obese su.

Obesity 84

Obesity Research 84

HCPLive

JULY 11, 2024

mg (Wegovy) confers benefit across the spectrum of NYHA functional class among patients with obesity-related HFpEF. A STEP-HFpEF analysis suggests semaglutide 2.4

Obesity 64

Obesity 64

American College of Cardiology

JUNE 4, 2024

The goal of the Dual vs. Single DCCV trial was to determine the efficacy and safety of dual direct-current cardioversion (DCCV) compared with single DCCV in patients with obesity and atrial fibrillation (AF) undergoing elective electrical cardioversion.

Obesity 54

Obesity Atrial Fibrillation Article 54

American College of Cardiology

JUNE 24, 2024

The goal of the SURMOUNT-OSA trial was to determine the effect of tirzepatide, both alone and in the setting of positive airway pressure (PAP) therapy, on obstructive sleep apnea (OSA) burden in patients with obesity.

Obesity 52

Obesity Article 52

CardiacWire

DECEMBER 6, 2023

The already massive GLP-1 obesity drug segment might have gained a major future competitor last week, following Roche’s acquisition of weight loss biotech Carmot Therapeutics. The biotech also has a once-daily dual GLP-1/GIP injectable (yes, daily) that’s in Phase 2 trials and would treat obese or overweight patients with type 1 diabetes.

Obesity 59

Obesity Diabetes 59

HCPLive

MAY 19, 2024

Peterson reviews the gastric and hormonal events linked to drugs like tirzepatide, before considering whether incretin therapies will help to finally embrace obesity as the medical condition it is.

Obesity 64

Obesity 64

American College of Cardiology

APRIL 10, 2024

What are the effects of semaglutide across a broad range of outcomes in people with obesity-related heart failure with preserved ejection fraction (HFpEF) with and without diabetes, and consistency across key patient subgroups?

Preserved Ejection Fraction 58

Preserved Ejection Fraction Obesity Heart Failure Diabetes 58

American College of Cardiology

MAY 29, 2024

The following are key points to remember from an American Heart Association scientific statement on the implementation of obesity science into clinical practice.

Obesity 52

Obesity Article 52

HCPLive

APRIL 28, 2024

This observational cohort study looked at the link between obesity and eczema, highlighting regional differences in the skin disease and obesity’s interdependence.

Obesity 52

Obesity 52

HCPLive

APRIL 20, 2024

During this segment of her interview at the ACP Internal Medicine Meeting, Jay discussed improving obesity care, telehealth utilization for patients, and more.

Obesity 59

Obesity 59

Frontiers in Cardiovascular Medicine

MARCH 7, 2024

We initiated a mobilization program, but the patient's mobility was highly limited due to severe obesity and symptomatic orthostatic hypotension. B-SES could be an option for patients with heart failure who have limited mobility and obesity. B-SES was introduced to accomplish weight loss and early ambulation.

Heart Failure 124

Heart Failure Obesity Heart Transplant Transplant 124

Medical Xpress - Cardiology

JANUARY 17, 2024

Young adults who reported higher stress during their teenage years to adulthood were more likely to have high blood pressure, obesity and other cardiometabolic risk factors than their peers who reported less stress, according to new research published in the Journal of the American Heart Association.

Blood Pressure 92

Blood Pressure Obesity Diabetes Risk Factors 92

Med Page Today

MARCH 8, 2024

(MedPage Today) -- Millions of Americans who have dropped pounds and boosted their health using popular obesity drugs like semaglutide (Wegovy) are facing a new dilemma: What happens if they stop taking them? Many worry, rightly, that they'll.

Obesity 76

Obesity 76

Frontiers in Cardiovascular Medicine

FEBRUARY 7, 2024

Background Aging is associated with a higher prevalence of sarcopenia, sarcopenic obesity (SO), and increased arterial stiffening, with possible detrimental effects on morbidity and mortality. The population was sorted into four subgroups: obese, sarcopenic, SO, and controls. SO had the highest value of cfPWV (15.18 ± 8.44 m/s),

Obesity 64

Obesity Hospital 64

American College of Cardiology

JUNE 24, 2024

Semaglutide reduces body weight to a greater extent in women with obesity-related heart failure with preserved ejection fraction (HFpEF) than in men, and improved Kansas City Cardiomyopathy Questionnaire Clinical Summary Score (KCCQ-CSS) to the same extent in both women and men, according to results from a prespecified secondary analysis of pooled (..)

Preserved Ejection Fraction 64

Preserved Ejection Fraction Obesity Heart Failure Cardiomyopathy 64

American College of Cardiology

MARCH 6, 2024

Bariatric surgery is effective in controlling hypertension (HTN) and polypharmacy in patients with obesity, according to results from the GATEWAY clinical trial published Feb. 5 in JACC.

Obesity 69

Obesity Hypertension Article 69

Journal of Clinical Investigation - Cardiology

FEBRUARY 15, 2024

Melanocortin 4 receptor (MC4R) mutations are the most common cause of human monogenic obesity and are associated with hyperphagia and increased linear growth. While MC4R is known to activate Gsα/cAMP signaling, a substantial proportion of obesity-associated MC4R mutations do not affect MC4R/Gsα signaling.

Obesity 75

Obesity 75

American College of Cardiology

MARCH 12, 2024

What are the trends in the estimated prevalence of underweight and obesity from 1990 to 2022 among adults and children across 200 countries and territories?

Obesity 49

Obesity Article 49

Cardiovascular Diabetology

JUNE 5, 2024

Cardiovascular disease (CVD) is closely associated with the triglyceride glucose (TyG) index and its related indicators, particularly its combination with obesity indices. However, there is limited research on.

Cardiovascular Disease 59

Cardiovascular Disease Obesity Research 59